Acrongenomics Announces New Validation Data Supporting Nano-JETA Technology as an Ultra-Fast, Robust Method for Nucleic Acid Amplification.

ATHENS, Greece -- Acrongenomics, Inc. (OTCBB:AGNM), a research and development nanobiotechnology company focused in the field of nanomolecular diagnostic applications, is pleased to announce a major milestone in further validating its Nano-JETA(TM) technology platform through an alternative method, Gel Electrophoresis, and the subsequent sequencing of the amplified genes. Nano-JETA(TM) technology offers great advantages compared to the performance of existing Real Time PCR by achieving nucleic acid amplification, detection and quantification in greatly reduced time (2 minutes for detection and quantification) with the option for isothermal (one-temperature) and non-isothermal protocols.

According to the validation data, Nano-JETA(TM) technology for Real Time PCR application generated consistent quantitative results from the 1st up to the 13th cycle. To further validate the specific amplification results, another method was used where all the amplified products were analysed by Gel Electrophoresis and documented by the BIO RAD Gel Doc EQ(TM) system. The results of the Gel Electrophoresis proved that the known number copies of genes of interest were amplified, visualized and detected in all copies range of levels studied (10-10,000,000 number of copies).

The Gel Electrophoresis bands of the genes of interest were isolated and sequenced by an independent laboratory and the results proved the specificity of our technology.

Due to the need for quantification from the 1st cycle, a quantification model was developed successfully where calculation of the number of copies is based on a new mathematical algebraic algorithm. Our model has already been tested against the existing approved software programs giving identical results when repeated six times with the same sets of experiments and using the same samples.

In comparison to the widely used PCR-based nucleic acid diagnostics, Nano-JETA(TM) Real Time PCR does not require special instrumentation. Our method validation generated conclusive evidence that Nano-JETA(TM) Technology offers key competitive advantages over conventional Real Time PCR, including:

--Achieving nucleic acid amplification detection and quantification at greatly reduced time (2 minutes for detection and quantification)

--Options for isothermal and non-isothermal protocols

--Increased selectivity, sensitivity and specificity

--Reproducibility and repeatability

--Compatibility and simplicity in use

Due to its robustness, speed and simplicity, Nano-JETA(TM) Real Time PCR has the potential to provide researchers and clinicians with highly sensitive, efficient and ultra-fast diagnostic assays that can be used in different diagnostic tests.